Bakar Labs转发了
It's official! Our MPCs are beating out the best in the business! We've known for decades that combination therapies are more effective at treating tumors, just like PrEP is a combination for preventing HIV. Catena's MPCs bring the benefits of combination therapies to the targeted delivery of an ADC. As you can see, the results speak for themselves!
CatenaBio's Multi-Payload Conjugates (MPCs) are officially outperforming the best ADCs in the clinic today, at least when it comes to in vivo models. Catena's MPCs were originally designed with a simple biological hypothesis based on decades of oncology research: that combinations are more effective than monotherapies. Today, this hypothesis is proven true with Catena's MPCs beating the current best-in-class ADC Enhertu in head-to-head studies.